Sanara MedTech/$SMTI
1D1W1MYTD1Y5YMAX
Capital at risk
About Sanara MedTech
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
- Ticker
- $SMTI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 108
- Headquarters
- Fort Worth, United States
- Website
- sanaramedtech.com
Sanara MedTech Metrics
BasicAdvanced
$322M
-
-$3.69
1.16
-
Price and volume
Market cap
$322M
Beta
1.16
52-week high
$35.34
52-week low
$16.05
Average daily volume
264K
Financial strength
Current ratio
2.577
Quick ratio
2.241
Long term debt to equity
6.068
Total debt to equity
6.116
Interest coverage (TTM)
1.41%
Profitability
EBITDA (TTM)
11.889
Gross margin (TTM)
93.03%
Net profit margin (TTM)
-29.15%
Operating margin (TTM)
9.34%
Revenue per employee (TTM)
$1,020,000
Management effectiveness
Return on assets (TTM)
7.64%
Return on equity (TTM)
-1.32%
Valuation
Price to revenue (TTM)
2.776
Price to book
40.58
Price to tangible book (TTM)
-24.92
Price to free cash flow (TTM)
67.675
Free cash flow yield (TTM)
1.48%
Free cash flow per share (TTM)
0.518
Growth
Revenue change (TTM)
12.96%
Earnings per share change (TTM)
217.42%
3-year revenue growth (CAGR)
22.57%
10-year revenue growth (CAGR)
39.39%
3-year earnings per share growth (CAGR)
51.87%
10-year earnings per share growth (CAGR)
7.93%
What the Analysts think about Sanara MedTech
Analyst ratings (Buy, Hold, Sell) for Sanara MedTech stock.
Analyst projections of the future price of Sanara MedTech stock.
Bulls say / Bears say
First-quarter revenue grew 19% year on year and Sanara achieved GAAP profitability from continuing operations. Management also reaffirmed 2026 revenue guidance of $116 million to $121 million, implying 13% to 17% growth. (GlobeNewswire)
The surgical portfolio is producing unusually high gross margins: second-quarter gross margin was 93%, while adjusted EBITDA rose to $5.0 million. First-half revenue increased 14%, led by an 11% rise in soft-tissue repair sales, supporting the case for a scalable core business. (Stockhouse, Last10K)
MiMedx has agreed to acquire Sanara for $35 per share, with the transaction valuing the business at about $350 million. The combination could broaden Sanara’s commercial reach, add scale across regenerative surgical products and support the planned 2027 launch of FDA Breakthrough Device-designated OsStic. (MiMedx, MassDevice)
Second-quarter revenue rose 9%, but it missed analysts’ estimate and the company posted a $0.4 million loss from continuing operations. Higher SG&A and interest costs outweighed the revenue gain, showing that growth is not yet translating consistently into bottom-line earnings. (StockTitan, Longbridge)
Sanara had $15.4 million of cash against $46.5 million of long-term debt at the end of June, while operating cash flow was negative for the first half. The $85 million 2026 minimum-revenue covenant leaves less room for an operational slowdown. (Last10K, StockTitan)
The proposed MiMedx acquisition still depends on shareholder approval, regulatory clearance and other closing conditions. If it fails, investors lose the near-term certainty of the $35-per-share consideration and face the standalone company’s leverage and execution risks. (MiMedx, StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 24 Sept 2026.
Sanara MedTech Financial Performance
Revenues and expenses
Sanara MedTech Earnings Performance
Company profitability
Upcoming events
No upcoming events
Sanara MedTech News
AllArticlesVideos
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
Business Wire2 weeks ago
SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders
Business Wire4 weeks ago
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI
Business Wire2 months ago
Funds containing Sanara MedTech
Fund name | Fund size | $SMTI weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.